Samsung Bioepis' Hadlima (biosimilar- adalimumab) Receives FDA's Approval for Autoimmune Diseases
Shots:
- The FDA’s approval is based on P-III clinical study assessing Hadlima vs reference product- Humira (adalimumab) in 544 patients in a ratio (1:1) with moderate to severe rheumatoid arthritis despite methotrexate therapy
- The P-III clinical study resulted in biosimilarity data of Hadlima to the reference product Humira- i.e- @24 wks. ACR20 (72.4% vs 72.2%). Hadlima is Samsung Bioepis’ third anti-TNF biosimilar which has received approval in the US
- Hadlima (adalimumab-bwwd) is a tumor necrosis factor (TNF) blocker- developed by Samsung Bioepis and will be commercialized by Merck in the US with its expected launch after Jun 30- 2019 in accordance with a licensing agreement signed with AbbVie
Click here to read full press release/ article
Ref: Businesswire | Image: Samsung Bioepis
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com